First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...

Related Keywords

United States ,Efthymiosn Deliargyris ,Cytosorbent Cytosorb ,Eric Kim ,Twitter ,Us Department Of Health ,Human Services ,Material Command ,National Institutes Of Health ,Us Air ,Corporate Communications ,European Union ,Facebook ,Us Army ,Blood Institute ,Cytosorbents Corporation ,National Heart ,Chief Medical Officer ,Breakthrough Designation ,Cytosorbents Breakthrough Device Designation ,Antithrombotic Removal ,Sorbents Corporation ,Use Authorization ,Antithrombotic Removal System ,Timely Antithrombotic Removal Ticagrelor ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Relations Contact ,Investor Relations ,